OTC:MSCLF
READ THE FULL MSCLF RESEARCH REPORT
Business Update
Positive Results for SAT-3247 in Multiple Mouse Models of Muscle Degeneration
On March 6, 2024, Satellos Biosciences Inc. (OTC:MSCLF) announced positive preclinical results were presented at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. A copy of the poster presentation can be found here. The results showed that SAT-3247 improved skeletal muscle function in three mouse models of muscle degeneration: mdx model of Duchenne Muscular Dystrophy (DMD), FLExDUX4 model of facioscapulohumeral muscular dystrophy (FSDH), and a muscle injury model in wildtype mice. An overview of the experimental models is given below.
In each experiment, mice were dosed orally at an intermittent frequency. Force measurements were collected from the hindlimbs at either day 21 (FSHD) or day 28 (DMD, injury). Injury model force was generated by ankle dorsiflexion. DMD and FSHD model force was generated by ankle plantar flexion. The following graphs show the force generation after treatment with different doses of SAT-3247 or placebo: *P<0.05, **P<0.01, ****P<0.00001
Satellos previously disclosed that Adapter Associated Kinase 1 (AAK1) was the drug target for the company’s DMD program. AAK1 belongs to the Numb-associated kinase (NAK) family of Ser/Thr protein kinases (Sorenson et al., 2008). It is implicated in a number of biological signaling pathways. Satellos is targeting it due to its role in the Notch signaling pathway, which plays an important role in satellite cell division and muscle cell regeneration (Bjornson et al., 2012).
Previous preclinical results presented by Satellos showed that SAT-3153 (the former lead development candidate) increases the percentage of asymmetric cell divisions in vitro, restores asymmetric cell division in vivo, and increases muscle force. Similar results were seen for SAT-3247. For an overview of the preclinical data the company has presented thus far for targeting AAK1, please see our previous reports (here and here).
Conclusion
Satellos continues to present very encouraging preclinical data for SAT-3247 and the most recent results provide evidence that the compound may have additional applicability in other muscle degenerative diseases. We continue to anticipate a first-in-human clinical trial for SAT-3247 in mid-2024. We have incorporated the potential for additional indications for SAT-3247 into our model, which has increased our valuation to $1.00 per share.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
